Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Morrow, V.C. Jordan.
Tamoxifen for breast cancer prevention: ready for prime time? (Editorial).
Breast J, 4 (1998), pp. 407-408
[2.]
N.K. Ibrahim, G.N. Hortobagyi.
New antiestrogens in breast cancer: a review.
Breast J, 4 (1998), pp. 213-229
[3.]
A. Fugh-Berman, S. Epstein.
Tamoxifen: disease prevention or disease substitution?.
Lancet, 340 (1992), pp. 1143-1145
[4.]
M.B. Sporn.
Quimioprevención del cáncer. Lancet (ed.
esp.), 24 (1994), pp. 229-231
[5.]
J.W. Morgan, J.E. Gladson, K.S. Rai.
Position Paper of the American Council on Science and Health on risk factors for breast cancer: established, speculated and unsupported.
Breast J, 4 (1998), pp. 177-197
[6.]
P.R. Etkind, J.A. Sparano.
Prevention.
Breast cancer (1.a ed.), pp. 55-67
[7.]
J.F. Cameselle, J.L. Puente.
Exploración clínica de la mama y atención primaria.
Rev Senología Patol Mam, 12 (1999), pp. 57-58
[8.]
S.L. Parker, K.J. Davis, P.A. Wingo, L.A.G. Ries, C.W. Heath.
Cancer statistics by race and ethnicity.
CA Cancer J Clin, 48 (1998), pp. 31-48
[9.]
S.H. Landis, T. Murray, S. Bolden, P.A. Wingo.
Cancer statistics.
CA Cancer J Clin, 48 (1998), pp. 6-29
[10.]
J.F. Cameselle.
Epidemiología y factores de riesgo del cáncer de mama en el sur de Galicia (tesis doctoral). Facultad de Medicina.
Universidad de Santiago de Compostela, (1988),
[11.]
World Health Orgatization.
World Health Statictics annual.
[12.]
J.L. Kelsey, P.L. Horn-Ross.
Breast cancer: magnitude of the problem and descriptive epidemiology.
Epidemiol Rev, 15 (1993), pp. 7-16
[13.]
D.M. Parkin, S.L. Whelan, J. Ferlay, L. Raymond, J. Young.
Cancer incidence in five continents. Vol VII.
[14.]
L. Garfinkel, C.C. Boring, C.W. Heath.
Changing trends: an overview of breast cancer incidence and mortality.
Cancer, 74 (1994), pp. 222-227
[15.]
M. Ruíz, F. Viciana.
Tendencia y distribución geográfica de la mortalidad por cáncer de mama en Andalucía (1976-1995).
Aten Primaria, 20 (1997), pp. 299-304
[16.]
A. Senra, R. Palmeiro, I. Herrero, J. Millán.
Evolution de la mortalite par cancer du sein en Espagne.
Bull Cancer, 74 (1987), pp. 427-431
[17.]
J. Rastam, L. Janzon, H. Olsson.
Rising incidence of breast among young women in Sweden.
Br J Cancer, 61 (1990), pp. 120-122
[18.]
M. Ewertz, B. Carstensen.
Trends in breast cancer incidence and mortality in Denmark 1943-1982.
Int J Cancer, 15 (1988), pp. 46-51
[19.]
E. White, J.R. Daling, T.L. Norsted, J. Chu.
Rising incidence of breast cancer among young women in Washington State.
J Natl Cancer Inst, 79 (1987), pp. 239-243
[20.]
SEER. Cancer Statistics Review1973-1995,
[21.]
C. Navarro, D. Pérez, J. Tortosa, G. Sánchez.
Incidencia del cáncer en Murcia en 1982. Murcia: Consejería de Sanidad, Consumo y Servicios Sociales de la C.A. de Murcia.
Monografía I, (1985),
[22.]
J. Abad, A. Arrazola, N. Ascunce.
Cáncer en Navarra. Registro de tumores 1973-82.
[23.]
J.M. Ruiz, J.M. Sanz, J. Alfaro, M.A. García-Pérez, O. Hörndler.
Cáncer de mama. Incidencia y mortalidad en la provincia de Soria.
Patología, 24 (1991), pp. 99-104
[24.]
J. Borrás, J. Galcerán, L.l. Anglada, et al.
El cáncer en Tarragona 1980-1985 Estudio epidemiológico descriptivo. Registro de cáncer de Tarragona. Monografía II.
[25.]
J.M. Cameselle, A. López, J.F. Cameselle.
Exploración clínica de la mama (cinta de vídeo).
Vigo, (1991),
[26.]
E.J. Sondik.
Breast cancer trends: incidence, mortality and survival.
Cancer, 74 (1994), pp. 995-999
[27.]
A. Senra, R. Palmeiro.
El cáncer y su prevención (1.a ed.).
[28.]
A. Senra.
La prevención primaria del cáncer. En: Academia Galega de Ciencias, editores. El cáncer, prevención y futuro (1.a ed.).
pp. 34-66
[29.]
N. Ascunce, A. Del Moral.
Programa de detección precoz de cáncer de mama en Navarra.
Rev Senología y Patol Mam, 3 (1990), pp. 96-103
[30.]
M. Prats, A. Marqués, J. Estapé, N. Ascunce, C. Herranz, A. Subías, et al.
Directrices para la puesta en marcha y desarrollo de las campañas de detección precoz del cáncer de mama en España.
Rev Senología y Patol Mam, 3 (1990), pp. 110-113
[31.]
L.A. Brinton.
Ways that women may possibly reduce their risk of breast cancer.
J Natl Cancer Inst, 86 (1994), pp. 1371-1372
[32.]
R.R. Love.
Prevention of breast cancer in premenopausal women.
J Natl Cancer Inst Monogr, 16 (1994), pp. 61-65
[33.]
R.R. Butrum, C.K. Clifford, E. Lanza.
NCI dietary guidlines: rationales.
American J Clin Nutr, 48 (1998), pp. 888-895
[34.]
B. Fisher, J.P. Constantino, C.K. Redmond, R. Poisson, D. Bowman, J. Coutuse, et al.
Ar Randomized clinical trial evaluating tamoxifen in the treatment of patients with node.negative breast cancer who have estrogen-receptor-positive tumors.
N Engl J Med, 320 (1989), pp. 479-484
[35.]
Breast Cancer Trials Comittee, Scottish Trials Office.
Adjuvant tamoxifen in the management of operable breast cancer: the Sottish trial.
Lancet, 2 (1987), pp. 171-175
[36.]
T. Fornander, L.E. Rutqvist, B. Cedervnark, O. Glas, A. Mattsson, C. Silverward, et al.
Adjuvant tamoxifen in early breast cancer: ocurrence of new primary.
Lancet, 1 (1989), pp. 117-120
[37.]
Early Breast Cancer Trialists’ Collaborative Group.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or imnune therapy. 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 comen.
Lancet, 339 (1992), pp. 1-15
[38.]
B. Fisher, J.P. Constantino, D.L. Wickerham, C.K. Redmon, M. Kavanah, W.M. Cronin, et al.
Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst, 90 (1998), pp. 1371-1385
[39.]
A. Buzdar, G.N. Hortobagyi, D. Frye, D. Ho, D.J. Booser, V. Valero, et al.
Bioequivalence of 20 mg once-daily tamoxifen relative to 10 mg twice-daily tamoxifen regimens for breast cancer.
J Clin Oncol, 13 (1994), pp. 50-54
[40.]
UICC.
International Union Against Cancer.
Screening for breast cancer,
[41.]
R.M. Simmon, M.P. Osborne.
Prophylactic mastectomy.
Breast J, 3 (1997), pp. 372-379
[43.]
F.J. Pérez, M. Ribeiro, L. Martínez, M. Ferrón, D. Gaspar, A. Ferrer, et al.
Mastectomía subcutánea: revisión de nuestra experiencia en 52 casos. En: Libro de resúmenes, XVIII Congreso Nacional de la Sociedad Española de Senología y Patología Mamaria.
Marbella, (1999), pp. c-22
[44.]
L.D. Ziegler, S.S. Droll.
Primary breast cancer after prophylactic mastectomy.
Am J Clin Oncol, 14 (1991), pp. 451-454
[45.]
V.R. Pennisis, A. Capozzi.
Subcutaneous mastectomy data: a final statistical analysis of 1500 patients.
Aesthetic Plast Surg, 13 (1989), pp. 15-21
[46.]
L.C. Hartmann, D.J. Schaid, J.E. Woods, T.P. Crotty, J.L. Myers, P.G. Arnold, et al.
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
N Engl J Med, 340 (1999), pp. 77-84
[47.]
M. Izquierdo.
Terapia génica y molecular en la cura del cáncer.
Biología molecular del cáncer, pp. 209-227
[48.]
S. Ramón y Cajal.
Carcinogénesis humana.
Rev Cancer, 13 (1999), pp. 116-128
[49.]
C.J. Fabian, B.F. Kimler.
Chemoprevention of breast cancer.
Breast J, 3 (1997), pp. 220-226
[50.]
S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, J.A. Cauley, et al.
The effect of raloxifene on risk of brest cancer in postmenopausal women.
JAMA, 281 (1999), pp. 2189-2197
[51.]
C. Fabian.
Who should receive which selective estrogen receptor modulater for prevention of breast cancer?.
Breast J, 5 (1999), pp. 211-214
[52.]
G. DePalo, T. Camerini, E. Marubini, M. Costa, F. Formelli, M Del Vecchio, et al.
Chemoprevention trial of contralateral breast cancer with fenretidine. Rationales, design, methodology, organization, data management, statistics and accrual.
Tumori, 83 (1997), pp. 884-894
[53.]
P.L. Crowell, W.S. Kennan, J.D. Haag, et al.
Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene.
Carcinogenesis, 13 (1992), pp. 1261-1264
[54.]
J. Torner, J. Cuzick.
Prevención farmacológica del cáncer de mama. Revisión del tema.
Rev Senología Patol Mam, 8 (1995), pp. 33-42
[55.]
C. Gómez, H. Cortés.
Quimioprevención en cáncer de mama. En: Cáncer de mama. Libro del año 1999.
pp. 143-152
[56.]
L. Pousa.
Estudio desde diversas perspectivas del selenio en el cáncer de mama (tesis doctoral).
[57.]
L. Pousa, M.E. Cortizo, J.F. Cameselle, J. Millos, J.J. Bosco, A. Senra.
Selenio y carcinogénesis mamaria.
Rev Senología Patol Mama 1999, 13 (2000), pp. 93-98
[58.]
J.F. Cameselle, L. Pousa, M.E. Cortizo, M.C. Campo, J. Millos, E. Lerma, et al.
Estudio de la actividad proliferativa y grado de diferenciación del cáncer de mama en relación con los niveles de selenio tisular. Resultados preliminares.
En: Libro de resúmenes, XVIII Congreso Nacional de la Sociedad Española de Senología y Patología Mamaria, Marbella, (1999), pp. c-70
[59.]
T. Powles, R. Eeles, S. Ashkey, D. Earton, J. Chang, M. Dowett, et al.
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
Lancet, 352 (1998), pp. 98-101
[60.]
V. Veronesi, P. Maisonneure, A. Costa, V. Sacchini, C. Maltoni, C. Robertson, et al.
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.
Lancet, 352 (1998), pp. 93-97
[61.]
V.C. Jordan, J.E. Glusman, S. Eckert, M. Lippman, T. Powles, A. Costa, et al.
Proccedings of the 34th Annual Meeting of the American Society Oncology, 466 (1998),
[62.]
M.J. Messina, V. Pensky, K.A. Setchell.
Soy intake and cancer risk: a review of the in-vitro and in-vivo data.
Nutr Cancer, 21 (1994), pp. 113-131
[63.]
D.P. Rose, A.P. Boyer, E.L. Wynder.
International comparisons of mortality rates for cancer of the breast, ovary, prostate and colon per capita food comsuption.
Cancer, 58 (1986), pp. 2363-2371
[64.]
D.L. McCormick, W.D. Johnson, K.V.N. Rao, R.A. Lubet, G.J. Kelloff.
Chemoprevention of rat mammary carcinogenesis: exceptional actvity of dictary dehydroepiandrosterone (DHEA).
J Cell Biochem, 17 (1993), pp. 253-254
[65.]
D.L. Page, W.D. Dupont.
Anatomic markers of human premalignancy and risk of breast cancer.
Cancer, 66 (1990), pp. 1326-1335
[66.]
F.A. Tavassoli, Y. Man.
Morphofunctional features of intraductal hyperplasia, atypical intraductal hyperplasia, and various grades of intraductal carcinoma.
Breast J, 1 (1995), pp. 155-162
[67.]
H.T. Lynch, J.N. Marcus, P. Watson, J. Lynch.
Cáncer de mama familiar, síndromes familiares de cáncer y predisposición al cáncer de mama. En: Bland/Copeland III. La mama. Manejo multidisciplinario de las enfermedades benignas y malignas.
[68.]
A. López-Touza.
Herencia y cáncer de mama. Tesis doctoral.
[70.]
L. Tabár, S.W. Duffy, K.B. Vita, H.H. Chen, T.C. Prevost.
The natural history of breast carcinoma.We have we learned from screening?.
Cancer, 86 (1999), pp. 449-462
[71.]
Wilson JMG.
Some principles of early diagnosis and detection.
Surveillance and early diagnosis in general practice, pp. 84-97
[72.]
S. Shapiro.
Then to fourteen years effects of breast cancer screening on mortality.
J Natl Cancer Just, 69 (1982), pp. 349
[73.]
V. Guillén, A. Llombart.
Screening del cáncer de mama. Avances y controversias. En: Cáncer de mama. Libro del año 1999.
pp. 113-128
[74.]
N.D. Rodes, C.W. Blackwell, C. Farrell.
Selección.
Cáncer de mama (2.a ed.), pp. 75-84
[75.]
D.M. Eddy.
Screening for breast cancer.
Ann Inter Med, 111 (1989), pp. 389-399
[76.]
D.B. Kopans.
La mama en imagen (2.a ed.).
[78.]
P.C. Stomper, D.J. D’Souza, P.A. DiNitto, M.A. Arredondo.
Analysis of parenchymal density on mammograms in 1353 women 25-79 years old.
Am J Roentgenol, 167 (1996), pp. 1261-1265
[79.]
I. Mittra.
In screening for breast cancer, clinical examination is as effective as mammography.
BMJ, 315 (1997), pp. 1234-1235
[80.]
D.V. Schapira, R.B. Levine.
Detección de cáncer mamario, apego a las indicaciones y valoración de las lesiones.
Clin Med Nort Am, 1 (1996), pp. 15-25
[81.]
D.B. Kopans.
The breast cancer screening controversy: lessons to be learned.
J Surg Oncology, 67 (1998), pp. 143-150
[82.]
R. Salvador.
Las campañas de despistaje de cáncer de mama.
Rev Senología Patol Mam, 2 (1989), pp. 193-196
[83.]
J. Torner, I. Fernández, J. Granell, E. Fraile, J. Cortés, A. Ruiz, et al.
Screening generalizado versus screening selectivo.
Rev Senología Patol Mam, 10 (1996), pp. 31-43
[84.]
J.M. Elwood, B. Cox, A.K. Richardson.
The effectiveness of breast cancer screening by mammography.
Curr Clin Trials doc, (1993), pp. 32
[85.]
K. Krelkowske, D. Grady, S.L. Rubin, C. Sandrock, V.L. Emster.
Efficacy of screening mamography. A meta-analysis.
JAMA, 273 (1995), pp. 149-154
[86.]
M.B. Barton, R. Harris, S.W. Fletcher.
Does this patient have breast cancer? The screening clinical breast examination: should it be done? How?.
JAMA, 282 (1999), pp. 1270-1280
[87.]
American Cancer Society.
Summary of American Cancer Society recommendations for the early detection of cancer in asymptomatic people.
[88.]
American Academy of Family Physicans.
Age charts for periodic health examination.
[89.]
American College of Obstetricians and Gynecologists.
The obstetrician-gynecologist and primary-preventive health care.
[90.]
The periodic health examination: 2. 1987 update.
Canadian Task Force on the Periodic Health Examination.
Can Med Assoc J, 138 (1988), pp. 620-621
[91.]
Neoplastic diseases.
En: U.S. Preventive Services Task Force. Guide to clynical preventive services.
[92.]
R.J. Womeodu, J.E. Bailey.
Barreras para la detección de cáncer.
Clin Med Nort Am, 1 (1996), pp. 11-128
[93.]
R. Matorras, C. Tacuri, M.L. Rodríguez, A. Moriche, G. Gutiérrez, P. Lobo, et al.
Análisis del conocimiento respecto al cáncer de mama en la población femenina.
Rev Senología Pato Mam, 5 (1992), pp. 29-34
[94.]
J.D. Bernà, M. Campos, R. Martínez, S. Gómez.
Modelo de selección de mujeres de alto riesgo de cáncer de mama.
Rev Senología Pato Mam, 3 (1990), pp. 187-191
[95.]
R. Ciurana, S. Calvet, C. Espel, J.M. Mendive, X. Cos, C. Pareja, et al.
Alternativas al cribado poblacional de cáncer de mama ¿Es útil la detección oportunística?.
Aten Primaria, 23 (1999), pp. 68-72
[96.]
J.M. Fernández-Hidalgo, T. Olmo, C. López-Muñiz.
Interacción de atención primaria, especializada y paciente en un programa de detección precoz del cáncer de mama.
Aten Primaria, 22 (1998), pp. 425-433
[97.]
C.M. Huguley, R.L. Brown.
The value of breast self-examination.
Cancer, 47 (1981), pp. 989-995
[98.]
S.W. Fletcher, M.S. O'Malley, J. Earp, T.M. Morgan, S. Lin, D. Degnan.
How best to teach women breast self-examination. A randomized controlled trial.
Ann Int Med, 112 (1990), pp. 772-779
[99.]
S.E. Taylor, R.R. Luchtman, J.V. Woo, A.Z. Bluming, G.M. Dosik, R.L. Leibowitz.
Breast self-examination among diagnosed breast cancer patients.
Cancer, 54 (1984), pp. 2528-2532
[100.]
J.M. Cameselle, A. López, J.F. Cameselle.
Autoexamen mamario (cinta de vídeo).
Vigo, (1991),
[101.]
J.D. Bernà, M. Campos, S. Martínez Gómez.
Práctica y enseñanza del autoexamen mamario.
Rev Senología Pato Mam, 3 (1990), pp. 244-247
[102.]
V.F. Semiglazov, V.M. Moiseenko, A.G. Manikhans, S.A. Protsenko, R.S. Kharikova, R.T. Popora, et al.
Interim results of a prospective randomized study of selfexamination for early detection of breast cancer (Rusia/St.Petersburg/WHO).
Vopr Onkol, 45 (1999), pp. 265-271
[103.]
A. Senra.
Principios de oncología clínica.
Rev San Hig Pub, 44 (1970), pp. 995-998
[104.]
M.E. Alonso-Doval.
Protocolo de enfermería en el diagnóstico y seguimiento de enfermas con cáncer de mama.
[105.]
J.A. Flórez.
La mujer ante el cáncer de mama: aspectos psicológicos.
Copyright © 2000. Elsevier España, S.L.. Todos los derechos reservados
